2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 2573

Lack of CD137-CD137 Ligand Signalling Aggravates Glomerulonephritis and Reduces the Survival of Lupus-Prone B6.MRLlpr Mice
Abstract Number: 1459

Lack of Drug-Drug Interaction between Filgotinib, a JAK-1 Selective Inhibitor, and a Representative Hormonal Contraceptive Medication, Levonorgestrel/Ethinyl Estradiol
Abstract Number: 1809

Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Abstract Number: 148

Lack of Screening By Rheumatologists and Primary Care Physicians for Childhood Sexual Abuse in Patients with Fibromyalgia-Depression Overlap: An Unrecognized Crisis?
Abstract Number: 1304

Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with SLE in Saginaw Valley, a High Risk Population
Abstract Number: 1089

Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry
Abstract Number: 865

Lasp-1 Regulates Cell-Matrix and Cell-Cell Contacts in Arthritic Mouse Models
Abstract Number: 2717

Late Onset of IgA Vasculitis Is Associated with More Severe Renal Involvement
Abstract Number: 2695

Latent Profile Analysis-Derived Typologies of Systemic Sclerosis Patients Using Body Image Indicators: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study
Abstract Number: 548

LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis
Abstract Number: 2209

Leptin and Adiponectin Mediate the Association between Body Mass Index and Hand and Knee Osteoarthritis
Abstract Number: 1982

Leptin, a Hypothalamic Signaling Hormone, Is Elevated in Fibromyalgia Patients
Abstract Number: 2968

Less Fatigue in Psoriatic Arthritis after High Intensity Interval Training. a Randomized Controlled Trial
Abstract Number: 1120

Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Abstract Number: 1644

Less Than Seven Hours of Sleep per Night Is Associated with Transitioning to Systemic Lupus Erythematosus
Abstract Number: 974

Leucine-Rich α-2 Glycoprotein Promotes Lung Fibrosis By Modulating TGF-β Signaling in Fibroblasts
Abstract Number: 515

Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
Abstract Number: 457

Levels of Satisfaction with RA Treatment and Associated Alignment between Rheumatologists and Their Patients across Latin America
Abstract Number: 1208

Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI: An Exploratory Study
Abstract Number: 2250

Linguistic Differences in Gout-Related Online Content: A Comparison of Professional Health Literature for Consumers Vs Patients’ Online Discussions of Gout
Abstract Number: 285

Liver X Receptor-α (LXRα) Modulates Macrophage Phenotype and Disease Activity in SLE
Abstract Number: 1721

Long Noncoding RNA H19X Is a Key Regulator of Apoptosis and Proliferation of Fibroblasts in Systemic Sclerosis and Other TGFβ-Driven Fibrotic Diseases
Abstract Number: 916

Long Term Effects of Early Childhood Thymectomy: A Population-Based Cohort Study of Association with Autoimmune Disease, Cancer, Infectious and Atopic Diseases
Abstract Number: 824

Long Term Efficacy and Safety of Intravenous and Subcutaneous Biologics in Large Vessels Vasculitis: 21 Patients Belonging to a Single Italian Center from 2011 to 2017
Abstract Number: 2722

Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases
Abstract Number: 2747

Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Abstract Number: 1909

Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Abstract Number: 231

Long Term Survival of Biological Agents in Patients with Axial Spondyloarthritis. the Impact of Sociodemographic Factors in Latin-America
Abstract Number: 601

Long-Term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects with Active Psoriatic Arthritis
Abstract Number: 1115

Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients
Abstract Number: 1498

Long-Term Cohort of Patients with a Clinical Diagnosis of Sjogren’s Syndrome: Activity Index and Patient Reported Outcome Performance
Abstract Number: 2437

Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
Abstract Number: 2272

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
Abstract Number: 1563

Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Abstract Number: 891

Long-Term Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis Treated Continuously over 52 Weeks: Results from Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Extension in Japan
Abstract Number: 1908

Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Abstract Number: 2440

Long-Term Efficacy, Safety and Immunogenicity Results from a Randomized, Double-Blind, Phase III Confirmatory Efficacy and Safety Study Comparing GP2017, a Proposed Biosimilar, with Reference Adalimumab
Abstract Number: 1292

Long-Term Follow-up of 320 Chilren Born to Mothers with Systemic Autoimmune Diseases: A Multicentre Survey from 24 Rheumatology Centers in Italy
Abstract Number: 2887

Long-Term Follow-up Report on Japanese Patients with Severe Systemic Sclerosis after Autologous Hematopoietic Stem Cell Transplantation
Abstract Number: 632

Long-Term Golimumab Retention Rate in Patients with Psoriatic Arthritis. Is Concomitant DMARD Important?
Abstract Number: 1808

Long-Term Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus
Abstract Number: 715

Long-Term Outcome of Demyelnating Syndrome in Systemic Lupus Erythematosus: A Longitudinal Study
Abstract Number: 713

Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Abstract Number: 2744

Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Abstract Number: 547

Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract Number: 2800

Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Abstract Number: 509

Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
Abstract Number: 2481

Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years
Abstract Number: 550

Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
Abstract Number: 944

Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Abstract Number: 2736

Long-Term Survival in Systemic Necrotizing Vasculitides
Abstract Number: 371

Longer Term Outcomes of Chronic Relapsing Multifocal Osteomyelitis in a UK Tertiary Adolescent and Young Adult Rheumatology Centre
Abstract Number: 1500

Longitudinal Analysis of Different Therapeutic Strategies in Patients with Primary Sjögren’s Syndrome
Abstract Number: 785

Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis
Abstract Number: 2808

Longitudinal Assessment of Cognitive Function in SLE: Identification of Trajectories
Abstract Number: 933

Longitudinal Association between Sleep Quality and Knee Pain in the Multicenter Osteoarthritis Study
Abstract Number: 32

Longitudinal Associations between Rheumatoid Factor and Ex Vivo Cytokine Production Reveal Novel Mechanistic Insights into Rheumatoid Arthritis
Abstract Number: 1495

Longitudinal Changes in EULAR Sjögren’s Syndrome Patient Reported Index in Routine Clinical Practice
Abstract Number: 2432

Longitudinal Changes in Gene Expression Associated with Disease Activity during Pregnancy and Post-Partum Among Women with Rheumatoid Arthritis
Abstract Number: 1864

Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
Abstract Number: 2131

Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation
Abstract Number: 1639

Longitudinal Evolution in a Nationwide Cohort Originally Classified As Mixed Connective Tissue Disease
Abstract Number: 1277

Longitudinal Predictors of Physical Function in Juvenile Myositis
Abstract Number: 1891

Low Alkaline Phosphatase Levels: Could It be Hypophosphatasia?
Abstract Number: 60

Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy
Abstract Number: 2911

Low Appendicular Bone Mass Predicts Mortality in Patients with Rheumatoid Arthritis
Abstract Number: 1677

Low Baseline Impedance in Proximal Esophagus and Decreased Pspw Index May Related with Pathogenesis of Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 582

Low Dose Computed Tomography Detects More Progression of Bone Formation in Comparison to Conventional Radiography in Patients with Ankylosing Spondylitis
Abstract Number: 2264

Low Educational Attainment Is Associated with Poor Patient Status in Rheumatoid Arthritis (RA) or Osteoarthritis (OA) at the Initial Rheumatology Visit, with Remarkably Similar Patterns in Either Diagnosis
Abstract Number: 1378

Low HDL Level As a Clinical Marker of Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 2033

Low Health Literacy Does Not Impact Adherence to Hydroxychloroquine in Patients with Systemic Lupus
Abstract Number: 20

Low Molecular Weight BAFF Receptor Antagonists Restrain Infiltration of B Cells into Organs of Autoimmune Model Mice By Suppressing B Cell Activation
Abstract Number: 2373

Low or High BMI Negatively Impacts RA Disease Activity in an Asian RA Cohort
Abstract Number: 500

Low Patient Global Assessment Scores in Rheumatoid Arthritis Are Associated with Pain and Physical Function in Patients Treated with Tofacitinib: A Post-Hoc Analysis of Phase 3 Trials
Abstract Number: 600

Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials
Abstract Number: 665

Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus
Abstract Number: 664

Low Vitamin D Is Associated with Thrombosis in Systemic Lupus Erythematosus
Abstract Number: 2675

Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Abstract Number: 1260

Lupus Diagnosis: Process and Patient Experience
Abstract Number: 188

Lupus Low Disease Activity State Is Associated with Reduced Direct Medical Costs in Patients with Systemic Lupus Erythematosus
Abstract Number: 1605

Lupus Low Disease Activity State Protects Against Most Subtypes of Organ Damage in SLE
Abstract Number: 1603

Lupus Low Disease Activity State: Can We Relax the Definition and Still Achieve Low Risk of SLE-Related Damage?
Abstract Number: 719

Lupus Nephritis in Isolation or Accompanied By Extra-Renal Manifestations: Early Lessons from the Accelerating Medicines Partnership
Abstract Number: 1600

Lupus Nephritis Is Associated with Increased Rates of Hospitalization for Adverse Events on a Glucocorticoid Toxicity Index and in-Hospital Mortality Compared with Non-Renal Lupus and Matched Controls: An Analysis of Insurance Claims Data
Abstract Number: 1786

Lupus Nephritis Is Linked to Immunity to an Intestinal Commensal Lachnospiracaea Species
Abstract Number: 1811

Lupus Patients, and Their Sisters, Have Higher Miscarriage Rates Than Healthy Women
Abstract Number: 2642

Lupus Serum Induces Glomerular Endothelial Cell Neutrophil Adhesion in Association with Soluble Mediators of Chemotaxis and Adhesion
Abstract Number: 1302

Luteinized Unruptured Follicle Syndrome in Young Female with Juvenile Idiopathic Arthritis

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].